Skip to content
Login Register

#antibody production

11 public questions tagged with this topic.

Immunological Applications

Myeloma cells used in hybridoma technology are selected to be:

Establishing stringent selection requires myeloma background auxotrophic for purine salvage, achieved by exposure to 8-azaguanine, purine analogue structurally similar to guanine. Salvage competent cells convert 8-azaguanine via HGPRT to 8-azaguanosine monophosphate incorporated into mRNA and rRNA causing miscoding, translational errors, and lethal proteotoxicity triggering unfolded protein response. Spontaneous HPRT1 mutants survive because they cannot metabolize analogue, accumulating no toxic nucleotides. Surviving subclones harbor frameshift, nonsense, or missense mutations in coding exons

Ref: Szybalski & Szybalska 1962 HGPRT negative mutants 8-azaguanine; ATCC SP2/0 Ag14 datasheet selection mechanism.

View Details
Immunological Applications

HAT medium contains:

HAT selective medium developed by John Littlefield in 1964 exploits metabolic auxotrophy to isolate somatic hybrids based on nucleotide salvage capability. Base medium DMEM or RPMI supplemented with fetal bovine serum provides carbon source, but three selective additives define HAT: hypoxanthine at 100 micromolar serving as purine base for salvage via hypoxanthine-guanine phosphoribosyltransferase converting to inosine monophosphate using phosphoribosyl pyrophosphate donor, thymidine at 16 micromolar supplying pyrimidine salvage substrate for thymidine kinase isoforms TK1 cytosolic and TK2 mit

Ref: Littlefield Science 1964 145:709 HAT selection; Szybalski Biochem Pharmacol HAT hypoxanthine aminopterin thymidine composition.

View Details
Immunological Applications

The main purpose of using myeloma cells in hybridoma technology is:

Primary plasma cells cannot be cultured long term because they activate intrinsic mitochondrial apoptosis via Bim upregulation when removed from survival niche provided by stromal cell contact, interleukin-6, and BAFF, plus replicative senescence triggered by telomere shortening each division. Myeloma cells circumvent these barriers through multiple oncogenic lesions: expression of hTERT telomerase reverse transcriptase adding TTAGGG repeats preventing crisis, disruption of p53-MDM2 axis, loss of cyclin dependent kinase inhibitors p16 and p21, autocrine loops via IGF-1 and interleukin-6 consti

Ref: Freshney Culture Animal Cells 7th ed myeloma immortality hTERT; Abbas Cellular Molecular Immunology hybridoma immortalization.

View Details
Immunological Applications

The main purpose of using myeloma cells in hybridoma technology is:

Primary B lymphocytes after differentiation short-lived plasma cells produce Ig extraordinary rate but survive 3-5 days culture due activation-induced death mediated Fas upregulation after strong BCR crosslinking and lack telomere maintenance somatic cells lacking telomerase entering senescence limited divisions dependence extrinsic survival signals CD40L helper T cells cytokines IL-4 IL-6 IL-21 follicular helper. Continuous monoclonal manufacturing over months requires immortalization essential. Myeloma plasmacytoma malignant transformation plasma cells proliferate indefinitely without exogen

Ref: Kohler Milstein Myeloma Immortality Principle 1975; Lodish Hybridoma Immortalization Mechanism Biology; Janeway Myeloma Fusion Purpose Immunobiology Chapter 2.

View Details
Immunological Applications

Hybridoma technology involves fusion of:

Somatic cell fusion underlying hybridoma merges two differentiated cell types each contributing specialized traits necessary monoclonal antibody manufacturing. Antigen-experienced B lymphocyte harvested spleen four days after final booster carries functionally rearranged Ig heavy VDJ and light VJ genes formed RAG1/RAG2 recombination junctional diversity somatic hypermutation conferring high affinity specificity target epitope active transcription intronic enhancer Emu 3 prime regulatory region capacity synthesizing Ig up to 2000 molecules per second but limited lifespan due lack telomerase dep

Ref: Janeway Hybridoma Fusion B cell Myeloma Mechanism 9th ed; Alberts Cell Fusion Mechanism Chapter 19; NCBI Kohler Milstein Hybridoma Methodology Original.

View Details
Immunological Applications

Monoclonal antibodies are produced by:

Monoclonal antibodies originate immortalized hybridoma lines fusing single antibody-secreting B lymphocyte with myeloma partner preserving exactly one immunoglobulin gene rearrangement producing uniform paratope. Protocol begins immunization BALB/c mice purified antigen HER2 extracellular domain mixed Freund's adjuvant stimulating germinal center spleen. Four days after final booster splenocytes enriched plasma blasts expressing high-affinity surface IgG harvested. Fusion mediated PEG 1500 or electrofusion aligning cells pearl chains creates heterokaryons containing nuclei both parents tetrapl

Ref: Kohler and Milstein Nature 1975 Hybridoma Monoclonal Generation; Janeway Hybridoma Technology Production Chapter 5; Lodish Antibody Production Hybridoma Cells Method.

View Details
Immunological Applications

Polyclonal antibodies differ from monoclonal antibodies because they:

Polyclonal antibody preparations heterogeneous mixture immunoglobulin molecules diverse B lymphocyte clones responding complex immunogen multiple antigenic determinants repetitive epitopes. Each naive B cell generates unique BCR random recombination RAG-mediated VDJ joining heavy chain variable diversity joining segments VJ joining light chain kappa lambda diversified junctional addition non-templated nucleotides TdT and somatic hypermutation germinal centers introducing point mutations rate 10^-3 per base division selecting higher affinity via follicular dendritic cell presentation. Immunizat

Ref: Janeway Immunobiology 9th ed Polyclonal vs Monoclonal Diversity Chap 5; NCBI Bookshelf Antibody Diversity Mechanism; Campbell Immunology Antibody Response Polyepitopic.

View Details
Basic Applied Biology

HAT medium selects hybridoma cells based on:

HAT medium selection developed by John Littlefield in 1964 exploits differential nucleotide anabolism pathways to isolate hybrid cells from mixture of parental populations. De novo purine and pyrimidine synthesis requires tetrahydrofolate-dependent enzymes, specifically aminopterin, a folate analog, competitively inhibits dihydrofolate reductase DHFR blocking de novo pathway. Alternative salvage pathway recycles hypoxanthine via hypoxanthine-guanine phosphoribosyltransferase HGPRT converting to IMP and thymidine via thymidine kinase TK to TMP, bypassing blocked de novo routes. Myeloma partners

Ref: Littlefield Science 1964 Selection of hybrids; Abbas Immunology 10th ed. HAT selection; Alberts Ch nucleotide metabolism salvage.

View Details
Basic Applied Biology

Hybridoma technology produces:

Hybridoma technology developed by Georges Köhler and César Milstein in 1975 and awarded Nobel 1984 created paradigm shift by immortalizing antibody-producing B lymphocytes through somatic cell fusion. Mice immunized with antigen develop germinal center reaction where B cells undergo VDJ recombination, somatic hypermutation and class switching to generate high affinity plasma cells. Splenic lymphocytes harvested shortly after boost are fused with HGPRT-deficient myeloma partner such as SP2/0-Ag14 or NS0 using polyethylene glycol 1500 that perturbs lipid bilayers promoting membrane fusion formin

Ref: Köhler & Milstein Nature 1975 Continuous cultures of fused cells; Abbas Cellular and Molecular Immunology 10th ed. monoclonal antibody generation.

View Details